Interpace Biosciences, Inc. (IDXGD) Stock Price & Analysis
Interpace Biosciences, Inc. (IDXGD) rose 6.19% to USD 6.91 as of September 8, 2026 at 07:34 UTC, according to Nexqual real-time market data.
IDXGD last closed at USD 6.51; the session ranged USD 6.5–6.7 on volume of 2,373 shares. Market capitalization is $38.30M, with a 52-week range of USD 0.77–7.8 (OID). Source: Nexqual, September 8, 2026 at 07:34 UTC.
Key Statistics (as of September 8, 2026 at 07:34 UTC)
| Price | USD 6.91 |
|---|---|
| Change | ▲ 6.19% (up) |
| Previous Close | USD 6.51 |
| Open | USD 6.7 |
| Day Range | USD 6.5 – 6.7 |
| 52-Week Range | USD 0.77 – 7.8 |
| Volume | 2,373 shares |
| Market Cap | $38.30M |
| Exchange | OID |
Technical Analysis (IDXGD)
Nexqual's technical model rates IDXGD "BUY" based on 5 bullish and 2 bearish signals across 128 daily candles, as of September 8, 2026 at 07:34 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 80.34 (overbought) |
| vs SMA50 | Above (USD 2.24) |
| MACD | 1.4 (positive) |
Analyst Ratings (IDXGD)
Wall Street analysts rate IDXGD "None", per Nexqual as of September 8, 2026 at 07:34 UTC.
| Consensus Rating | None |
|---|
Earnings (IDXGD)
Source: Nexqual, September 8, 2026 at 07:34 UTC.
Financials & Fundamentals (IDXGD)
| Total Revenue | $36.14M |
|---|---|
| Revenue Growth (YoY) | -1.10% |
| Gross Margin | +63.75% |
| Operating Margin | +3.52% |
| Profit Margin | +67.64% |
| ROE | +225.68% |
| Debt / Equity | 4.19 |
| Current Ratio | 2.22 |
| Total Cash | $2.69M |
| Total Debt | $974,000 |
| Free Cash Flow | $3.42M |
Source: Nexqual, September 8, 2026 at 07:34 UTC.
Financial Health Score (IDXGD)
Nexqual rates Interpace Biosciences, Inc.'s overall financial health "Mixed" across five dimensions, as of September 8, 2026 at 07:34 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $3M cash, no debt |
| Cash Flow | Solid — Operating cash flow $4M |
| Efficiency | Strong — ROE 226%, ROA 11.1% |
Ownership (IDXGD)
| Insider Ownership | +91.18% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 5.54M |
| Float | 360,998 |
| Short % of Float | +1.18% |
Source: Nexqual, September 8, 2026 at 07:34 UTC.
Leadership (IDXGD)
Interpace Biosciences, Inc. is led by Thomas W. Burnell (age 63), President, CEO & Chairman, per Nexqual as of September 8, 2026 at 07:34 UTC.
| President, CEO & Chairman | Thomas W. Burnell (age 63) |
|---|---|
| CFO & COO | Christopher McCarthy (age 33) |
From Interpace Biosciences, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Interpace Biosciences, Inc. provides molecular diagnostic tests and pathology services for evaluating cancer risk in the United States.
- It offers ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules.
- The company also provides ThyraMIR v2, which assesses thyroid nodules for malignancy risk using a proprietary microRNA gene expression classifier.
- It primarily serves physicians, cancer centers, clinics, laboratories, pathology groups, and hospitals.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PULM | Pulmatrix, Inc. | USD 1.39 | ▼ 5.44% |
| GLBS | Globus Maritime Limited | USD 3.69 | ▼ 3.4% |
| CBIO | Crescent Biopharma, Inc. | USD 20.88 | ▲ 12.62% |
| RNVA | Rennova Health, Inc. | USD 0 | ▲ 0% |
| CFOR | CapForce Inc. | USD 5.15 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 07:34 UTC. This page is informational and not investment advice.